Amedisys

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amedisys reports robust Q4 earnings, eyes growth amidst operational challenges

Amedisys showcases strong financial performance and strategic initiatives for 2023, focusing on growth and operational optimization.
Despite challenges like labor market issues and operational hurdles, the company remains confident in its growth strategies and talent management.
Opportunities in negotiations with payers, talent acquisition, and operational enhancements position Amedisys for continued success and revenue growth.
With a positive outlook for 2023 and a resilient approach to challenges, Amedisys is poised for steady growth and operational improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The High Acuity Care segment includes providing home care recovery for high acuity patients on either a full risk or limited risk basis. The company was founded in 1982 and is headquartered in Baton Rouge, LA.

UnitedHealth Group

Amedisys Inc said on Monday it had received an unsolicited proposal from UnitedHealth Group's health services company Optum to acquire all of its outstanding shares in an all-cash transaction worth $3.26 billion.

Amedisys gets over $3 billion unsolicited offer from UnitedHealth's Optum

Option Care Health

Amedisys Board Determines Optum Proposal Could Reasonably be Expected to Result in a Superior Proposal

Amedisys Announces Receipt of Unsolicited Proposal From Optum

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amedisys, Inc. (NasdaqGS: AMED) to Option Care Health, Inc. ("Option Care") (NasdaqGS: OPCH). Under the terms of the proposed transaction, shareholders of Amedisys will receive 3.0213 shares of Option Care for each share of Amedisys that they own. KSF is seeking to determine whether this consideration and the.

AMEDISYS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amedisys, Inc. - AMED

NEW YORK , May 4, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Amedisys, Inc. (NASDAQ: AMED) and its board of directors concerning the proposed merger of the company with Option Care Health, Inc. (NASDAQ: OPCH). Stockholders will receive 3.0213 shares of Option Care Health common stock for each share of Amedisys stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Merger of Amedisys, Inc.

Amedisys (AMED) sees a year-over-year decline in the Hospice segment's revenues.

Amedisys (AMED) Q1 Earnings Beat Estimates, Margins Dip

While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amedisys (AMED) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

MILWAUKEE , May 3, 2023 /PRNewswire/ -- Ademi LLP is investigating Amedisys (NASDAQ: AMED) for possible breaches of fiduciary duty and other violations of law in its transaction with Option Care Health.  Click here to learn how to join the action https://www.ademilaw.com/case/amedisys-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Amedisys, Inc. has obtained a Fair Price in its transaction with Option Care Health

Amedisys (AMED) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $1.23 per share a year ago.

Amedisys (AMED) Q1 Earnings Top Estimates

BATON ROUGE, La. , May 3, 2023 /PRNewswire/ -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2023.

AMEDISYS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES 2023 GUIDANCE

All-Stock Transaction Combines Highly Complementary Businesses Unlocking Significant Benefits for Patients, Providers, Payers, and Care Teams Increases Access to High Quality Care for Communities Across the U.S. through a Unique National Clinical Platform Comprehensive Capabilities Across Alternate Site Care Spectrum Position Combined Company to Move Deeper into Value-Based Care Highly Attractive Combined Financial Profile Which Generated $6.2 Billion in Revenues and $622 Million in Adjusted EBITDA on a Combined Basis for Full Year 2022 Creates Stockholder Value Including Through Anticipated Annual Run-Rate Revenue and Cost Synergies of Approximately $75 Million by Year Three Following Close Companies to Host Joint Conference Call and Webcast at 5:30 p.m. ET Today, May 3, 2023, to Discuss Transaction BANNOCKBURN, Ill.

Option Care Health and Amedisys to Combine Creating a Leading, Independent Platform for Home and Alternate Site Care

For Amedisys (AMED), dealing with the continuous shortage of clinical labo, in nursing in particular, has been challenging.

Amedisys (AMED) New Buyouts Aid Growth, CMS Ruling Unfavorable

Amedisys's (AMED) share price is likely to grow following an impressive fourth-quarter 2022 performance and new partnerships.

Here's Why You Should Retain Amedisys (AMED) Stock for Now

HouseWorks and Amedisys form Care Coordination Partnership to Enhance Amedisys Personal Care Network HouseWorks and Amedisys form Care Coordination Partnership to Enhance Amedisys Personal Care Network

HouseWorks Announces Acquisition of Amedisys' Personal Care Division

BATON ROUGE, La., March 23, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, and high-acuity care, supports the findings from the NORC at the University of Chicago study released by the National Association for Home Care & Hospice (NAHC) and the National Hospice and Palliative Care Organization (NHPCO) today that demonstrates the value of hospice care.

Amedisys Supports New Research that Demonstrates the Value of Hospice Care Through Better Outcomes and Medicare Savings

Healthcare leader brings wealth of operational and business development experience Healthcare leader brings wealth of operational and business development experience

Amedisys Board Appoints Richard Ashworth as New President and Chief Executive Officer

BOULDER, Colo. , March 9, 2023 /PRNewswire/ -- nVoq Incorporated, the in-home healthcare industry's leading provider of HIPAA compliant speech recognition solutions, collaborated with Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, and high-acuity care, to present outcomes realized during a 2022 joint study of speech recognition impact on documentation quality at the PALTC23 conference in Tampa, Florida (March 9-12, 2023).

Amedisys and nVoq Present Outcomes from Speech Recognition Study at PALTC23 Conference

BATON ROUGE, La., March 09, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, today announced that Paul Kusserow, Chairman and Chief Executive Officer and Scott Ginn, Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer, will present at Oppenheimer's 33rd Annual Healthcare Conference on March 14th at 10:00 a.m. ET and at the Barclays Global Healthcare Conference on March 15th at 8:50 a.m. ET.

Amedisys to Present at Multiple Healthcare Conferences in March

Amedisys (AMED) delivers strong Home Health performance in the fourth quarter amid cost pressure.

Amedisys (AMED) Q4 Earnings Beat, Operating Margin Dips

Amedisys, Inc. (NASDAQ:AMED ) Q4 2022 Earnings Conference Call February 16, 2023 11:00 AM ET Company Participants Nick Muscato - Chief Strategy Officer Paul Kusserow - Chairman & CEO Scott Ginn - EVP, CFO & Acting COO Adam Holton - Chief People Officer Conference Call Participants Brian Tanquilut - Jefferies Matthew Larew - William Blair & Company Justin Bowers - Deutsche Bank Joanna Gajuk - Bank of America Merrill Lynch Andrew Mok - UBS Tao Qiu - Stifel, Nicolaus & Company Benjamin Hendrix - RBC Capital Markets Benjamin Mayo - SVB Securities John Ransom - Raymond James & Associates Scott Fidel - Stephens Inc. Gary Taylor - Cowen and Company A.J. Rice - Crédit Suisse Operator Greetings and welcome to the Amedisys Fourth Quarter 2022 Earnings Conference Call.

Amedisys, Inc. (AMED) Q4 2022 Earnings Call Transcript

Amedisys (AMED) delivered earnings and revenue surprises of 12.62% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Amedisys (AMED) Surpasses Q4 Earnings and Revenue Estimates

Amedisys and HouseWorks form Care Coordination Partnership to Enhance Amedisys Personal Care Network Amedisys and HouseWorks form Care Coordination Partnership to Enhance Amedisys Personal Care Network

Amedisys Announces Divestiture of its Personal Care Division

Program focuses on enhancing quality of life for members in Middle Tennessee in their homes Program focuses on enhancing quality of life for members in Middle Tennessee in their homes

Amedisys Partners with BlueCross BlueShield of Tennessee to Provide Palliative Care at Home to Members

BATON ROUGE, La., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2022.

Amedisys Reports Fourth Quarter and Year-End 2022 Financial Results, Issues 2023 Guidance, Announces Sale of Its Personal Care Line of Business and Signs Innovative Palliative Care at Home Partnership With BlueCross BlueShield of Tennessee

BATON ROUGE, La., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, today announced that its Board of Directors has authorized a stock repurchase program, under which the Company may repurchase up to $100 million of its outstanding common stock through December 31, 2023.

Amedisys Board of Directors Authorizes $100 Million Stock Repurchase Program

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Amedisys Stock (AMED)